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Abstract
Background: Light-to-moderate alcohol consumption has been reported to be cardio-protective among apparently
healthy individuals; however, it is unclear whether this association is also present in those with disease. To examine
the association between alcohol consumption and prognosis in individuals with pre-existing cardiovascular disease
(CVD), we conducted a series of meta-analyses of new findings from three large-scale cohorts and existing
published studies.
Methods: We assessed alcohol consumption in relation to all-cause mortality, cardiovascular mortality, and
subsequent cardiovascular events via de novo analyses of 14,386 patients with a previous myocardial infarction,
angina, or stroke in the UK Biobank Study (median follow-up 8.7 years, interquartile range [IQR] 8.0–9.5), involving
1640 deaths and 2950 subsequent events, and 2802 patients and 1257 deaths in 15 waves of the Health Survey for
England 1994–2008 and three waves of the Scottish Health Survey 1995, 1998, and 2003 (median follow-up 9.5
years, IQR 5.7–13.0). This was augmented with findings from 12 published studies identified through a systematic
review, providing data on 31,235 patients, 5095 deaths, and 1414 subsequent events. To determine the best-fitting
dose-response association between alcohol and each outcome in the combined sample of 48,423 patients, models
were constructed using fractional polynomial regression, adjusting at least for age, sex, and smoking status.
Results: Alcohol consumption was associated with all assessed outcomes in a J-shaped manner relative to current
non-drinkers, with a risk reduction that peaked at 7 g/day (relative risk 0.79, 95% confidence interval 0.73–0.85) for
all-cause mortality, 8 g/day (0.73, 0.64–0.83) for cardiovascular mortality and 6 g/day (0.50, 0.26–0.96) for
cardiovascular events, and remained significant up to 62, 50, and 15 g/day, respectively. No statistically significant
elevated risks were found at higher levels of drinking. In the few studies that excluded former drinkers from the
non-drinking reference group, reductions in risk among light-to-moderate drinkers were attenuated.
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Conclusions: For secondary prevention of CVD, current drinkers may not need to stop drinking. However, they
should be informed that the lowest risk of mortality and having another cardiovascular event is likely to be
associated with lower levels of drinking, that is up to approximately 105g (or equivalent to 13 UK units, with one
unit equal to half a pint of beer/lager/cider, half a glass of wine, or one measure of spirits) a week.
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Background
Lifestyle and dietary habits play an important role in the
secondary prevention of cardiovascular disease (CVD) [1].
However, the impact of alcohol consumption on CVD pa-
tients’ prognosis is unclear and recommendations for pa-
tients regarding upper limits of drinking vary substantially
across different guidelines [2–5]. While light-to-moderate
alcohol consumption is associated with a lower risk of de-
veloping multiple cardiovascular outcomes in general
population cohorts [6, 7], it is difficult to extend the pos-
ited cardio-protective effects to CVD patients because of
their typically older age and compromised vasculature as
well as the medications they take to prevent secondary
events [8]. In addition, for CVD patients, there are con-
cerns about the potential detrimental effects of alcohol on
the circulatory system, such as hypertension, arrhythmias,
and haemorrhagic stroke, which may exacerbate their
existing pathological conditions [9].
The most recent meta-analysis to have explored the
association between alcohol consumption and prognosis
among CVD patients was undertaken by Costanzo et al.
in 2010 [10]. Pooling data from eight observational stud-
ies published between 1998 and 2008, they identified a
maximal 22% relative risk (RR) reduction at approxi-
mately 8 g/day for cardiovascular mortality and 18% at 7
g/day for all-cause mortality among patients with myo-
cardial infarction (MI), angina, or stroke, relative to non-
drinkers, with risk increasing in a dose dependent man-
ner above these levels. However, their analysis was lim-
ited to studies only on mortality and did not consider
any non-fatal outcomes. Understanding how alcohol
consumption is related to cardiovascular morbidity is of
great importance to CVD patients because this popula-
tion is at high risk of recurring cardiovascular events
which can significantly compromise the patients’ quality
of life [11]. Including morbidity information will comple-
ment the existing evidence base to provide a more
complete picture of how alcohol consumption can be
managed for optimal secondary CVD prevention. Add-
itionally, further studies [12–14] have been published in
the decade since the last meta-analysis. Given the grow-
ing debate on this topic, a more detailed and compre-
hensive reassessment of the evidence is warranted in the
absence of long-term clinical trials [9].
We thus analysed individual data from three large-
scale cohorts. In addition to estimating risk of mortality
among CVD patients, we also examined the association
between alcohol intake and subsequent cardiovascular
events. To consolidate all available evidence on this
topic, we conducted meta-analyses of our results with
those from published studies identified through a sys-
tematic review.
Methods
De novo cohort analyses
Study cohorts and participants
Data were obtained from participants in the Health Sur-
vey for England (HSE), the Scottish Health Survey
(SHeSs), and UK Biobank. Descriptions of each cohort
are provided in Additional file 1 (Appendix S1). The
present analyses combined data from the 1994–2008
HSE datasets and the 1995, 1998, and 2003 SHeSs data-
sets and were restricted to participants aged ≥16 years
reporting to have been diagnosed with MI/angina (not
recorded separately) or stroke prior to baseline. For UK
Biobank, we identified participants with MI, angina, or
stroke before recruitment based on record linkage to the
Hospital Episode Statistics (HES), using algorithms de-
fined in Additional file 1 (Appendix S1 and Table S1
[15–29]).
To be eligible for the analysis, participants in HSE/
SHeSs and UK Biobank had to have baseline information
about their drinking status and average alcohol intakes,
plus age, sex, smoking status, self-reported history of
diabetes and hypertension, socioeconomic position/edu-
cation, body mass index, and regular medications. We
separated former drinkers from never drinkers and cate-
gorised current drinkers into three groups: low-level
drinkers (≤ 14 units/week, one unit contains 8g of etha-
nol [30] and is equivalent to half a pint of beer/lager/
cider, half a glass of wine, or one measure of spirits/for-
tified wine [31]), medium-level drinkers (>14 to ≤50
units/week for men, >14 to ≤35 units/week for women),
and high-level drinkers (>50 units/week for men, >35
units/week for women) [32]. Further details of the alco-
hol assessment and covariates are described in Add-
itional file 1 (Appendix S1).
We assessed alcohol consumption in relation to three
outcomes (each ascertained by national death registries
or HES records): all-cause mortality, cardiovascular mor-
tality, and major cardiovascular events. We defined car-
diovascular events as a composite of angina, fatal and
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non-fatal MI and stroke, revascularisation procedures
(angioplasty or coronary artery bypass graft), death from
heart failure, and sudden cardiac death, and only UK
Biobank contributed data to the analysis on cardiovascu-
lar events. Participants were followed up until the date
of their death or first detected event, or were censored
on the date they left the UK or the last date of data link-
age (cohort specific). Additional details of outcome as-
certainment and follow-up procedures are in Additional
file 1 (Appendix S1).
Statistical analysis
We used multivariable Cox proportional hazard models
to calculate hazard ratios (HRs) and 95% confidence in-
tervals (CIs) for the associations of different drinking
categories with each outcome of interest relative to
never drinkers. Adjustments were made for age, sex, and
smoking status in initial models and then for all covari-
ates in maximally-adjusted models. For HSE/SHeSs data-
sets, we additionally adjusted for survey wave using
shared-frailty models to account for within-group corre-
lations. Schoenfeld residuals were plotted to ascertain
that the proportional hazards assumption had not been
violated (see Additional file 1: Figure S1). Models for
MI, angina and stroke as primary event in further strati-
fied analyses were adjusted for each other as well as all
covariates.
Systematic review and meta-analysis
Search strategy and study selection
This study followed PRISMA and MOOSE guidelines
[33, 34]. MEDLINE and Embase were searched for rele-
vant studies up to 30 July 2020, using a combination of
subject headings and free-text terms with no restrictions
on language or publication date (see Additional file 1:
Table S2). In addition, the reference lists of eligible stud-
ies and a previous systematic review [35] on this topic
were manually checked to add any studies missed by the
initial database searches.
After removing duplicates, citations were screened to
exclude any that did not report a prospective relation-
ship between alcohol consumption and outcomes of
interest among patients with pre-existing CVD. Full text
of the remaining citations were then independently
assessed by two pairs of reviewers (CD and AB/DON)
for eligibility. Studies were retained if they met the selec-
tion criteria for study design (longitudinal study includ-
ing randomised control trials not involving alcohol),
study population (MI, angina, or stroke patients), expos-
ure (alcohol consumption reported across ≥3 categories,
inclusive of a non-drinking group, to allow for testing a
curvilinear relationship), outcomes (all-cause or cardio-
vascular mortality, cardiovascular events), and risk esti-
mates (at least adjusted for age, sex, and smoking). We
excluded studies if the reported alcohol consumption
could not be converted into gram per day or if frequency
counts, risk estimate, and its corresponding 95%CI were
not available after contacting the authors. The inter-
rater agreement for this review was high (Fleiss κ= 0.85).
Data extraction and quality assessment
Data extraction was conducted by one reviewer (CD)
and then verified by a second reviewer (AB/DON).
When available, we collected data on the amount of al-
cohol consumed. Given that most studies included in
our analyses reported alcohol consumption on a daily
basis, we used grams of alcohol per day as the common
unit of measurement. To convert the number of drinks
to grams in four included studies (one conducted in Italy
[12] and three in USA [36–38]) which did not specify
the quantity of alcohol in one drink, we assumed
country-specific standard drinks (i.e. Italy 12g, USA 14g)
[39]. A factor of 0.79 was used for the conversion of
millilitres to grams (i.e. 1 ml alcohol = 0.79 g [40]) in
one study [41]. Exposures categorised according to time
periods longer than 1 day were transferred into daily es-
timates, assuming an even distribution of consumption
over the reference period. Where averages were not re-
ported for each drinking category, the midpoints of the
range were chosen. For open-ended upper categories,
mean values were defined as 1.2 times the lower bound-
ary as suggested by Berlin et al. [42]. Similar results were
obtained when multiplying the lower boundary for the
open-ended upper categories by 1.0, 1.4, or 1.6 instead
of 1.2 (see Additional file 1: Figure S2).
Multiple alcohol measures were used in three included
studies, two of which reported risk estimates based on the
average intakes during follow-up [13, 43] and the
remaining one performed time-dependent analyses to
allow changes on drinking habits [12]. In addition, most of
the included studies asked patients to report their average
consumption since the occurrence of their primary events
(post-event alcohol assessment), whereas three studies
used alcohol intake in the year prior to primary events
(pre-event), assuming drinking habits remained stable
over time, even following events [14, 44, 45].
Because all included studies except one [46] used a
non-drinking reference group, we preferred risk esti-
mates for different drinking categories versus non-
drinkers. For a single study that used occasional drinkers
as the reference group [46], the risk estimates were
recalculated to derive alternative estimates each relative
to a non-drinker group. A Microsoft Excel spreadsheet
developed by Hamling et al. was used during the recal-
culation to account for the non-independence between
estimates sharing a common reference group [47]. When
a study reported risk estimates with different degrees of
statistical adjustment for confounding, we used the
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most-adjusted one. Furthermore, to investigate the pos-
sible impact of over-adjustment for potential mediators
on our results, we performed a sensitivity analysis by
using risk estimates that were only controlled for age,
sex, and smoking, the three most important confounding
factors for the alcohol-CVD relationship. With all esti-
mates reported being RR or HR, RR served as the com-
mon measure of association across studies. HRs were
treated as measures of RRs [48]. Study quality was
assessed using the Newcastle-Ottawa Scale (see Add-
itional file 1: Appendix S2) [49].
Data synthesis
For each analysis, a family of second-degree fractional
polynomial models (FP2: log RR = β1x
p1 +β2x
p2, x0 equals
log(x) rather than 1 and the model becomes log RR = β1x
p
+ β2x
plog(x) when p1 = p2) was generated to derive a
power transformation of the exposure variable [50]. p1
and p2 were taken from a predefined set P= (−2, −1, −0.5,
0, 0.5, 1, 2, 3) which allows for a very large and varied set
of functions, including U- and J-shaped curves, to be gen-
erated. For x = 0, the function would start from log RR =
0 and therefore no constant term (i.e. the intercept) was
considered in our models [51]. The best fit among the
family of models was defined as that with the lowest
deviance.
With the terms of exposure identified in the best-
fitting FP2, a two-stage regression model was fitted to
summarise the relationship between alcohol consump-
tion and each outcome of interest. The first stage gener-
ated the dose-response model within each study and the
second stage pooled study-specific trends using a ran-
dom effect model to accommodate the heterogeneity
across studies [52, 53]. A sensitivity analysis was done by
excluding studies of the lowest quality and pre-defined
subgroup analyses according to sex, primary event, and
type of non-drinking reference group and alcohol assess-
ment for each outcome of interest.
The overall degree of heterogeneity was quantified
using the I2 index [54]. We assessed evidence of publica-
tion bias through visual inspection of funnel plots and
Egger’s regression test for asymmetry [55]. All statistical
analyses were performed using Stata (version 15.1).
Results
Associations of alcohol consumption with mortality and
cardiovascular morbidity in study cohorts
Complete data for the de novo cohort analyses were
available for 2802 participants (MI/angina=2341, stroke=
535) in HSE/SHeSs and 14,386 (MI=5333, angina=9589,
stroke=2064) in UK Biobank (see Additional file 1: Fig-
ure S3). On average, UK Biobank participants were
younger and reported higher consumption of alcohol
than HSE/SHeSs participants (Table 1).
During a median follow-up of 9.5 years (interquartile
range [IQR], 5.7–13.0) in HSE/SHeSs and 8.7 years
(IQR, 8.0–9.5) in UK Biobank, we identified 1257 deaths
among HSE/SHeSs participants and 1640 deaths among
UK Biobank participants, of which 492 (39.1%) and 631
(38.5%) deaths were due to cardiovascular causes, re-
spectively. Maximally adjusted models of UK Biobank
dataset revealed a J-shaped association for both all-cause
and cardiovascular mortality, with low- and medium-
level drinkers having a decreased risk compared with
never drinkers but no difference in risk for high-level or
former drinkers (Fig. 1). Although similar J-shaped
trends were observed for HSE/SHeSs, none of the asso-
ciations were statistically significant, probably due to the
relatively small sample size of each drinking subgroup
(Fig. 1). We noted differential associations by sex and
primary cardiovascular events in stratified analyses (see
Additional file 1: Figures S4 and S5).
A total of 2950 fatal and non-fatal subsequent cardio-
vascular events were recorded in UK Biobank, with a
median follow-up of 7.5 years (IQR, 6.8–8.5). A lower
risk of cardiovascular events was observed across all cat-
egories of current drinkers (Fig. 1), within participants of
both sexes and with different primary events (see Add-
itional file 1: Figures S4 and S5).
Characteristics of studies included in meta-analysis
Of the initial 1722 unique citations, 12 published studies
fulfilled the selection criteria (see Additional file 1: Fig-
ure S6). Table 2 outlines the characteristics of all studies
selected for meta-analyses, inclusive of HSE/SHeSs and
UK Biobank. Nine of the 14 studies had a cohort design
and the remaining five [12, 36–38, 43] were randomised
control trials for certain drug or diet type with no spe-
cific inventions on alcohol consumption. The quality of
selected studies was moderate to high on average, with a
median score of 8 on the Newcastle-Ottawa Scale. Add-
itional details regarding alcohol consumption, effect esti-
mates, and confounder adjustment are provided in
Additional file 1 (Tables S3–S5).
Alcohol consumption and all-cause mortality among CVD
patients
Eleven studies, comprising 41,743 CVD patients, con-
tributed to this analysis. Overall, a J-shaped association
was observed, with a protective effect that peaked at 7 g/
day and remained significant up to 62 g/day (Fig. 2A,
Table 3). Although the dose-response trend followed a J-
curve in men, we found no increased risk among women
at higher levels of drinking (see Additional file 1: Figure
S7). Regarding primary events, moderate drinking was
associated with a lower risk for total mortality among
patients with a previous MI or angina, but not with
stroke (see Additional file 1: Figure S8). Pooled analysis
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of estimates relative to non-current drinkers showed a
reduced mortality risk for an alcohol intake up to ap-
proximately 75 g/day. However, when studies with
former drinkers in the reference group were excluded,
the association was considerably weakened (see Add-
itional file 1: Figure S9). In addition, among those stud-
ies using post-event alcohol measures, the result did not
change substantively; a similar trend was seen in studies
with multiple measures but failed to reach statistical sig-
nificance, probably because of the low number of curves
(n=2) in this subgroup (see Additional file 1: Figure
S10).
Alcohol consumption and cardiovascular mortality among
CVD patients
Nine studies, comprising 24,770 patients, were included
in the meta-analysis on cardiovascular mortality, and the
overall association with alcohol consumption was inter-
preted as a J-curve. The maximal reduction in mortality
risk was found to be 27% at 8 g/day and the reversion
Fig. 1 Association of drinking categories with all-cause mortality, cardiovascular mortality, and cardiovascular events by study cohorts. Hazard
ratios are adjusted for age, sex, smoking status, diabetes, hypertension, socioeconomic position or education, body mass index, and regular use of
cholesterol-lowering medications, antihypertensive medications, antiplatelet agents, digoxin, and warfarin. CI indicates confidence interval; HR,
hazard ratio; HSE, the Health Survey for England; SHeSs, the Scottish Health Survey
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point was reached at 50 g/day (Fig. 2B, Table 3). Our re-
sults remained little altered when considering studies on
men only, or using different types of reference groups or
alcohol assessments (see Additional file 1: Figures S7, S9
and S10). Unlike the J-curve observed for men, there
was no excess risk of mortality among women at higher
levels of consumption (see Additional file 1: Figure S7).
Stratified analyses by primary events showed that mod-
erate drinking was associated with a lower risk of cardio-
vascular mortality among patients with a previous MI;
however, among those with angina or stroke, the overall
dose-response trend was close to null (see Additional
file 1: Figure S8).
Alcohol consumption and cardiovascular events among
CVD patients
Among the four studies (28,621 patients) addressing
drinking and cardiovascular events, one reported dose-
response trend separately for two age groups and thus
provided two curves. Alcohol intake was associated with
a significant reduction in the risk of cardiovascular
events up to 15g/day (Fig. 2C, Table 3). Pooled analysis
of studies on women showed a declined risk for an alco-
hol intake up to approximately 49 g/day, whereas no re-
duction in risk was seen in men at any level of
consumption (see Additional file 1: Figure S7). Moderate
drinking was found to be protective against cardiovascu-
lar events within patients of different primary events and
studies with multiple alcohol measures (see Additional
file 1: Figures S8 and S10). However, when studies in-
cluding former drinkers in the reference group were ex-
cluded, the overall protective effect was attenuated and
became non-significant (see Additional file 1: Figure S9).
Sensitivity analyses
Sensitivity analyses excluding studies of the lowest qual-
ity (score <7) revealed similar curves (see Additional
file 1: Figure S11). Results were consistent when restrict-
ing analysis to estimates that were only adjusted for age,
sex, and smoking status (see Additional file 1: Figure
S12). For mortality outcomes, there was no evidence of
heterogeneity across the first- and second-order polyno-
mial (both I2 = 0%); however, a high degree of hetero-
geneity (both I2 = 75%) was noted in studies
Fig. 2 Overall dose-response relationship between alcohol consumption and risk of mortality and subsequent cardiovascular events, using maximally-
adjusted estimates. Best-fitting second-degree fractional polynomial models (with 95% CIs) are shown in solid curves with each data point overlaid as
circles. Circle size indicates the weighting of each data point and is inversely proportional to the variance of the log-transformed relative risk
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contributing results for cardiovascular events. For all
outcomes assessed, we found no evidence of publication
bias (see Additional file 1: Figure S13).
Discussion
Meta-analysis of the results from three major UK co-
horts together with those from 12 published studies
found J-curve relationships between alcohol consump-
tion and mortality in those with cardiovascular disease,
with the greatest risk reduction being observed at 7 g/
day for all-cause mortality and 8 g/day for cardiovascular
mortality relative to current non-drinkers. This dose-
response trend remains consistent with the last pub-
lished meta-analysis [10] and has also been reported in
Table 3 Best-fitting models and results of the meta-analysis on alcohol consumption and risk of mortality and subsequent
cardiovascular events





Maximal effect sizea Reversion
point, g/
dayb
Powers for the Best-Fitting FP2
RR (95% CI) g/day dose_1 dose_2
All-cause mortality
Overall 11 (11) 41,743 0.79 (0.73–0.85) 7 62 −0.5 1
Male 6 (6) 19,897 0.82 (0.72–0.93) 9 39 0 0.5
Female 3 (3) 6046 0.64 (0.36–1.14) 54 49 −2 3
MI as primary event 9 (9) 29,554 0.82 (0.68–0.99) 2 7 −1 0.5
Angina as primary event 2 (2) 8938 0.79 (0.63–0.99) 39 46 0.5 3
Stroke as primary event 3 (3) 3618 0.71 (0.42–1.20) 12 NA 0 0.5
Reference group including former drinkers 9 (9) 41,405 0.77 (0.69–0.85) 16 75 −0.5 2
Reference group excluding former drinkers 4 (4) 17,526 0.85 (0.71–1.00) 3 3 −0.5 −0.5
Post-event alcohol assessment 8 (8) 37,245 0.81 (0.74–0.88) 9 52 0 0.5
Multiple alcohol measures 2 (2) 12,337 0.78 (0.59–1.03) 16 NA −0.5 −0.5
Cardiovascular mortality
Overall 9 (9) 24,770 0.73 (0.64–0.83) 8 50 0 0.5
Male 5 (5) 14,536 0.72 (0.62–0.85) 9 32 0 0.5
Female 2 (2) 4790 0.29 (0.09–1.01) 54 54 0 2
MI as primary event 6 (6) 12,422 0.76 (0.64–0.91) 3 25 −2 3
Angina as primary event 2 (2) 8934 0.72 (0.42–1.23) 56 NA 3 3
Stroke as primary event 3 (3) 3617 0.63 (0.37–1.08) 26 NA 0 3
Reference group including former drinkers 6 (6) 24,269 0.73 (0.58–0.93) 13 27 0 0.5
Reference group excluding former drinkers 5 (5) 17,683 0.71 (0.55–0.90) 7 29 −0.5 0.5
Post-event alcohol assessment 7 (7) 21,525 0.73 (0.60–0.90) 8 43 0 0
Multiple alcohol measures 1 (1) 1818 0.58 (0.40–0.84) 17 33 −0.5 3
Cardiovascular events
Overallc 4 (5) 28,621 0.50 (0.26–0.96) 6 15 −2 −2
Male 3 (4) 13,598 0.56 (0.23–1.34) 8 NA −2 −2
Female 1 (1) 3775 0.67 (0.43–1.05) 54 49 −2 3
MI as primary event 4 (5) 20,361 0.79 (0.66–0.94) 11 35 −2 3
Angina as primary event 1 (1) 8747 0.69 (0.59–0.81) 35 n.a. −2 1
Stroke as primary event 1 (1) 1855 0.49 (0.26–0.92) 72 n.a. −2 3
Reference group including former drinkers 3 (3) 25,983 0.72 (0.53–0.97) 40 45 1 1
Reference group excluding former drinkers 2 (3) 17,020 0.78 (0.46–1.31) 17 NA 3 3
Multiple alcohol measures 1 (1) 353 0.32 (0.14–0.71) 38 n.a. 2 3
FP2 second-degree fractional polynomial model, MI myocardial infarction
aDefined as the lowest point of the dose-response curve within the range of dose reported by the studies
bDefined as the dose of alcohol at which protection against the outcome is no longer statistically significant at the 95% confidence level; not applicable (NA) if
non-significant association was found at any level of consumption; not available (n.a.) if the association remained significant within the range of dose reported by
the studies
cAll of the four studies measured post-event alcohol consumption and had a quality score ≥ 7
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other high-risk populations, such as hypertensive [57]
and diabetic individuals [58].
To our knowledge, this is the first meta-analysis of al-
cohol consumption and any subsequent cardiovascular
events in patients with previous CVD, in which UK Bio-
bank contributed nearly half of the total sample size. We
found a reduction in risk for an alcohol intake up to ap-
proximately 15 g/day, an upper limit much lower than
those for the mortality outcomes. Taken together, our
study suggested that, among CVD patients, the upper
drinking limit for lower risks of mortality and cardiovas-
cular morbidity was about 105 g/week, which was lower
than those recommended in most current guidelines.
For example, the American Heart Association (AHA)
and American College of Cardiology Foundation 2011
guidelines on secondary prevention recommend “alcohol
moderation”—up to 196 g/week (2 USA drinks/day) for
male and 98 g/week (1 USA drink/day) for female ac-
cording to the national dietary guidelines [59]—for pa-
tients with atherosclerotic vascular disease [2]; the same
recommendations apply in the AHA/American Stroke
Association 2014 guidelines for secondary stroke preven-
tion [5]; the UK National Institute for Health and Care
Excellence 2020 guidelines recommend to keep alcohol
intake within 112 g/week (14 UK units/week) for both
men and women after having an MI [4]; and WHO 2007
recommendations for prevention of recurrent MI and
stroke were no more than about 166 g/week (3 units/
day, 1 unit contains 10 ml of pure alcohol) [3].
Strengths and limitations of study
With almost triple the number of CVD patients, our
study expands the findings of the last comprehensive re-
view published a decade ago [10]. In particular, both
HSE/SHeSs and UK Biobank provide long-term follow-
up of large contemporary samples from the UK general
population. The inclusion of these new datasets allows
us to examine the risk of drinking within various sub-
groups, some of which are not available or too small to
reliably investigate in published studies. For example,
our data suggest that the dose-response associations of
alcohol with mortality and morbidity differ by sex and
are more pronounced among patients with MI than an-
gina or stroke. These findings raise the question of
whether differential drinking limits should be recom-
mended in patient subgroups and warrant further inves-
tigation. Furthermore, there is evidence that reductions
in risk of all-cause mortality and subsequent events
might have been overestimated due to the inclusion of
former drinkers in the non-drinking reference group.
Former drinkers may include individuals who have quit
drinking in response to ill health (i.e. “sick quitters”),
particularly past heavy drinkers [60], therefore making
current drinkers appear healthy relative to less healthy
non-current drinkers. This could lead to a low-risk
drinking limit less than the estimated 105g/week; how-
ever, we cannot definitely determine the extent of this
overestimation with very few studies that explicitly ex-
cluded former drinkers.
Many medications commonly used by CVD patients
can interact with alcohol by altering the metabolism or
effects of the medication and/or alcohol [61]. The inter-
actions may occur with lower amounts of alcohol or fol-
low a dose-response relationship, with the risk and
severity of interactions increasing with increasing levels
of alcohol consumption [62]. For example, moderate
drinking in combination with statins use may be syner-
gistic to confer a lower risk of all-cause mortality [63].
Concurrent heavy drinking with warfarin enhance the
anticoagulant effect and may lead to major bleeding
[64]. In the present meta-analyses, most (9 out of 14)
but not all included studies adjusted for medication use
(including antihypertensives, cholesterol-lowering and
oral antiplatelet agents) in their most-adjusted models
and so there is a possibility of residual confounding by
medications. However, sensitivity analyses showed con-
sistent results when using risk estimates that were only
adjusted for age, sex and smoking, suggesting that fur-
ther adjustment for medication use is unlikely to materi-
ally impact on our findings.
In the present study, no elevated risk of mortality and
cardiovascular events was found at higher levels of alco-
hol consumption, which is in line with other meta-
analysis among CVD patients [10, 65] but contradicts
evidence from some of the general population studies
[66, 67]. The discrepancy between the present study and
previous general population studies may be partly due to
the generally older age of CVD patients. The mean/me-
dian age at baseline was greater than 59 years in most
datasets used in our analyses. Because alcohol-related
risk is relatively higher among younger people compared
with the elderly [68], enrolling older participants in stud-
ies would minimise the risk relationship compared with
an analysis that included drinkers of all ages. Notably,
with older age of the study participants comes increased
likelihood for drinkers to become former drinkers, which
might exacerbate the “sick quitters” bias (i.e. when the
non-drinking reference group also includes former
drinkers who have stopped drinking due to poor health)
as discussed above. Patients who drink heavily and en-
rolled in studies at older ages are more likely to repre-
sent “healthy survivors” or have safer drinking patterns
[60, 69]. Particularly heavy drinkers are known to be
under-represented in some datasets used in our analyses,
such as the Physicians’ Health Study [70] and HSE/
SHeSs [71]. These potential selections may have biased
downwards the estimated associations between heavy in-
take and risks of mortality and subsequent events.
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Furthermore, most included studies did not capture the
extremes of drinking and therefore may be underpow-
ered to look at the effects of very heavy drinking. Conse-
quently, the absence of effects at higher levels of
consumption seen in our study should be interpreted
cautiously, particularly in light of the increasing con-
cerns about alcohol misuse among older people [72] as
well as the known wider health and societal impacts in
regard to these [73].
The present study has some further limitations. First,
as a composite of cardiac mortality and several non-fatal
cardiovascular endpoints, the definition of cardiovascular
events varied across the three published studies [12, 41,
43], and thus, we defined the outcome in UK Biobank
using the most frequently reported events in these stud-
ies. However, there was still a significant heterogeneity
in the pooled analysis. Recent observational and genetic
evidence has suggested that drinking at moderate levels
is associated with a decreased risk of some but not all
forms of CVD [6, 74–76]. Therefore, this heterogeneity
might have reflected the complex and diverse impacts of
alcohol consumption on different CVD outcomes.
Secondly, our results must be interpreted with cau-
tion when it comes to some subgroups that have been
examined in only a limited number of studies. Although
the included studies scored as moderate-to-high quality
on the Newcastle-Ottawa Scale, this may not account
for some pertinent design/reporting characteristics of
many of the studies which had problems that were spe-
cific to alcohol exposure and not covered in the scale.
For example, by relying upon only a single measure-
ment of alcohol consumption, some studies did not
consider the effect of temporal changes in drinking be-
haviour both after primary event and during follow-up;
however, our results remained consistent in the ana-
lyses restricted to studies using post-event or multiple
measures. Further analyses for beverage type were not
possible with sufficient beverage-specific data reported
in very few studies.
Thirdly, episodic heavy drinking has been suggested to
modify the relationship between average alcohol con-
sumption and CVD/mortality risk [77]. Our results
might have been confounded by the drinking pattern, as
the selected studies did not exclude “binge” drinkers.
Additionally, as with all observational studies and self-
reported alcohol intake, our findings are prone to bias;
however, self-reported drinking data was validated
against high-density lipoprotein cholesterol and gamma-
glutamyl transferase in HSE/SHeSs and UK Biobank (see
Additional file 1: Table S6). Although we attempted to
minimise confounding by using the most adjusted esti-
mates, information on dietary habits or physical activity
was not available in all studies included in our meta-
analysis and residual confounding may still persist.
Conclusions
In summary, our study shows that an alcohol intake up
to about 105g (or equivalent to 13 UK units, with one
unit equal to half a pint of beer/lager/cider, half a glass
of wine, or one measure of spirits) a week is associated
with lower risks of both mortality and subsequent car-
diovascular events among CVD patients. While this
threshold is somewhat lower than those recommended
in most current guidelines, specific recommendations re-
garding the downward revision of such guidelines cannot
be made. There is some indication that reductions in
risk may have been overestimated by studies using a ref-
erent group contaminated by less healthy former
drinkers. No evidence of elevated risk among heavy
drinkers was found but this was potentially attributable
to selections and under-representation of such drinkers
in the datasets. Moreover, when developing drinking
thresholds for use within guidelines, we must consider
the totality of evidence and balance pragmatic concerns
[78]. Our findings therefore indicate that, for secondary
prevention of CVD, current drinkers may not need to
stop drinking but should be informed that lower levels
of intake (up to 105g/week) may be associated with re-
duced risks. However, non-drinking patients should not
be encouraged to take up light drinking because of well-
known adverse effects on other health outcomes, such as
cancers [79].
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